within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD22_MetforminAndEvogliptin;

model MetforminAndEvogliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD22;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD22</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metformin and evogliptin is a fixed-dose combination oral antidiabetic medication. Metformin is a biguanide that decreases hepatic glucose production and increases insulin sensitivity, while evogliptin is a DPP-4 inhibitor that increases incretin levels, thereby promoting glycemic control. This combination is used to manage type 2 diabetes mellitus in adults, and is approved in some countries for clinical use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult (age 18-65 years) with type 2 diabetes mellitus, assuming no significant renal or hepatic impairment. No published population PK models specific to metformin/evogliptin FDC as of June 2024. Estimates based on available PK data for single compounds.</p><h4>References</h4><ol><li><p>Rhee, SJ, et al., &amp; Yu, KS (2016). Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. <i>Drug design, development and therapy</i> 10 1411–1418. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S102459&quot;>10.2147/DDDT.S102459</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27110098/&quot;>https://pubmed.ncbi.nlm.nih.gov/27110098</a></p></li><li><p>Rhee, SJ, et al., &amp; Yu, KS (2016). Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. <i>Drug design, development and therapy</i> 10 2525–2534. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S110712&quot;>10.2147/DDDT.S110712</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27570447/&quot;>https://pubmed.ncbi.nlm.nih.gov/27570447</a></p></li><li><p>Bajaj, S, et al., &amp; Sharma, A (2021). Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus. <i>The Journal of the Association of Physicians of India</i> 69(2) 25–29. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33527807/&quot;>https://pubmed.ncbi.nlm.nih.gov/33527807</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndEvogliptin;
